Worldwide: Food and Drugs Law

On April 23, 2026, the U.S. Department of Justice (DOJ), in conjunction with the Drug Enforcement Administration (DEA), announced that pursuant to President Trump's December 18, 2025, Executive Order "Increasing Medical Marijuana and Cannabidiol Research," issuance of a final rule by way of Attorney General order (Order) that immediately placed both U.S. Food and Drug Administration (FDA)-approved products containing marijuana and marijuana products regulated by a state medical marijuana license in Schedule

Entrepreneurs and business leaders in the cannabis industry face unique challenges in launching and sustaining successful enterprises, from navigating complex legislative hurdles to securing financing and building community partnerships.

As the Fiscal Year 2027 (FY27) budget and appropriations process kicks into full swing this month, the release of the President’s budget and related congressional hearings provide opportunities to gain insight into both the Trump administration’s and congressional lawmakers’ areas of focus for the Department of Health and Human Services, including the Food and Drug Administration (FDA).

The Trump administration has signaled growing support for psychedelic medicine through a recent executive order and cabinet-level statements, focusing particularly on ibogaine research for treating PTSD, opioid dependence, and other mental health conditions in veterans. While these developments represent meaningful institutional backing, significant legal and regulatory obstacles remain before psychedelics can move from Schedule I classification to approved medical treatments.

Building on the Trump administration’s efforts to crack down on deceptive direct-to-consumer (DTC) prescription drug advertising, the Food and Drug Administration (FDA) has recently requested new authority from Congress to more strictly regulate DTC drug advertisements.

Few industries in recent American history have climbed so fast or stand to fall so hard. The hemp-derived THC beverage industry went from virtually nonexistent in 2018 to a market worth an estimated $1.375 billion ...

What Happened: On April 2, the U.S. Environmental Protection Agency (EPA) published the draft Sixth Contaminant Candidate List (CCL 6) pursuant to its authority under the Safe Drinking Water Act...

On April 14, 2026, the Centers for Medicare and Medicaid Services (“CMS”) published a proposed rule[1] that would require faster prior authorization (“PA”) decisions...

Consumer demand for GLP‑1 drugs such as Ozempic and Zepbound continues to surge, fueling rapid growth in the market for GLP-1 drugs and compounded GLP-1 products, as well as supplements...